Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/182214
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Sánchez-Martínez, Diego | es_ES |
dc.contributor.author | Allende-Vega, Nerea | - |
dc.contributor.author | Orecchioni, Stefania | - |
dc.contributor.author | Talarico, Giovanna | - |
dc.contributor.author | Cornillon, Amelie | - |
dc.contributor.author | Vo, Dang-Nghiem | - |
dc.contributor.author | Rene, Celine | - |
dc.contributor.author | Lu, Zhao-Yang | - |
dc.contributor.author | Krzywinska, Ewelina | - |
dc.contributor.author | Anel Bernal, Luis Alberto | - |
dc.contributor.author | Gálvez Buerba, Eva Mª | - |
dc.contributor.author | Pardo, Julián | - |
dc.contributor.author | Robert, Bruno | - |
dc.contributor.author | Martineau, Pierre | - |
dc.contributor.author | Hicheri, Yosr | - |
dc.contributor.author | Bertolini, Francesco | - |
dc.contributor.author | Cartron, Guillaume | - |
dc.contributor.author | Villalba, Martín | - |
dc.date.accessioned | 2019-05-23T13:02:59Z | - |
dc.date.available | 2019-05-23T13:02:59Z | - |
dc.date.issued | 2018-06-14 | - |
dc.identifier.citation | Theranostics 8(14): 3856-3869 (2018) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/182214 | - |
dc.description | 6 Figuras | es_ES |
dc.description.abstract | Monoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical results have been poor. Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, daratumumab, cetuximab and trastuzumab. Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, they overcome certain anti-apoptotic mechanisms found in leukemic cells. Conclusion: We have established a new protocol for activation/expansion of NK cells with high ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer treatment. | es_ES |
dc.description.sponsorship | This work was supported by an AOI from the CHU Montpellier (N°221826;GC/MV), La Ligue Regionale contre le Cancer (GC), Fondation de France (0057921;MV), the PRT-K program 2018 (MV/GC/BR), the “Investissements d’avenir” Grant LabEx MAbImprove: ANR-10-LABX-53 (GC/PM/BR) and the NK 001 projet financed by the "Fonds Europeen de Developpement Regional (FEDER-FSE-IEJ 2014/2020) et par la region Occitanie Pyrénées-Méditerranée, SAF2014- 54763-C2-1-R (JP), SAF2017-83120-C2-1-R (JP) and SAF2014-54763-C2-2-R (EMG) from Spanish Ministry of Economy and Competitiveness. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Ivyspring International Publisher | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2014- 54763-C2-1-R | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2017-83120-C2-1-R | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2014-54763-C2-2-R | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | NK cells | es_ES |
dc.subject | Monoclonal antibodies (mAbs) | es_ES |
dc.subject | Antibody-dependent cell cytotoxicity (ADCC) | es_ES |
dc.subject | Cancer | es_ES |
dc.title | Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.7150/thno.25149 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.7150/thno.25149 | es_ES |
dc.identifier.e-issn | 1838-7640 | - |
dc.rights.license | https://creativecommons.org/licenses/by-nc-sa/4.0/ | es_ES |
dc.contributor.funder | Université de Montpellier | es_ES |
dc.contributor.funder | Ligue Nationale contre le Cancer (France) | es_ES |
dc.contributor.funder | Institut National du Cancer (France) | es_ES |
dc.contributor.funder | Université de Tours | es_ES |
dc.contributor.funder | Institut National de la Santé et de la Recherche Médicale (France) | es_ES |
dc.contributor.funder | Centre National de la Recherche Scientifique (France) | es_ES |
dc.contributor.funder | Institut National de la Recherche Agronomique (France) | es_ES |
dc.contributor.funder | Centre Hospitalier Régional Universitaire de Tours | es_ES |
dc.contributor.funder | Institut du Cancer de Montpellier | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Région Occitanie / Pyrénées-Méditerranée | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | Centre Hospitalier Régional Universitaire de Montpellier | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004099 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100001677 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100006364 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004794 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100006488 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100008222 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100005261 | es_ES |
dc.contributor.orcid | Allende-Vega, Nerea [0000-0001-5569-6461] | es_ES |
dc.contributor.orcid | Orecchioni, Stefania [0000-0002-6781-7002] | es_ES |
dc.contributor.orcid | Talarico, Giovanna [0000-0001-5051-6468] | - |
dc.contributor.orcid | Anel Bernal, Luis Alberto [0000-0002-5175-8394] | - |
dc.contributor.orcid | Gálvez Buerba, Eva Mª [0000-0001-6928-5516] | - |
dc.contributor.orcid | Martineau, Pierre [0000-0002-7993-7183] | - |
dc.contributor.orcid | Bertolini, Francesco [0000-0001-5660-3255] | - |
dc.contributor.orcid | Cartron, Guillaume [0000-0003-0659-9635] | - |
dc.contributor.orcid | Villalba, Martín [0000-0002-4385-4888] | - |
dc.identifier.pmid | 30083264 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (ICB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Theranostics 2018_8.pdf | Artículo principal | 1,81 MB | Adobe PDF | Visualizar/Abrir |
thnov08p3856s1.pdf | Información suplementaria | 16,32 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
36
checked on 20-abr-2024
SCOPUSTM
Citations
43
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
43
checked on 29-feb-2024
Page view(s)
362
checked on 23-abr-2024
Download(s)
183
checked on 23-abr-2024